Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil, rituximab, or both. The index was subsequently validated by merging three independent cohorts of MALT lymphoma patients (including 633 patients).
The score is based on 3 simple clinical parameters that were able to discriminate patient prognosis into 3 risk groups (low, intermediate, and high) predictive for event-free and overall survival. The score was also able to discriminate prognosis for patients with gastric or non-gastric MALT lymphoma.
References
Thielblemont et al.
A MALT lymphoma prognostic index generated from the dataset of the IELSG-19 prospective clinical trial.
Blood 2017. DOI 10.1182/blood-2017-03-771915.
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]